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Abstract
Background: Validation of the use of the lognormal model for predicting long-term survival rates
using short-term follow-up data.
Methods: 907 cases of laryngeal cancer were treated from 1973–1977 by radiation and surgery
(248), radiation alone (345), and surgery alone (314), in registries of Connecticut and Metropolitan
Detroit of the SEER database, with known survival status up to 1999. Phase 1 of this study used the
minimum chi-square test to assess the goodness of fit of the survival times of those who died with
disease to a lognormal distribution. Phase 2 used the maximum likelihood method to estimate long-
term survival rates using short-term follow-up data. In order to validate the lognormal model, the
estimated long-term cancer-specific survival rates (CSSR) were compared with the values
calculated by the Kaplan-Meier (KM) method using long-term data.
Results: The 25-year CSSR were predicted to be 72%, 68% and 65% for treatments by radiation
and surgery, by radiation alone, and by surgery alone respectively, using short-term follow-up data
by the lognormal model. Corresponding results calculated by the KM method were: 72+/-3%, 68+/
-3% and 66+/-4% respectively.
Conclusions: The lognormal model was validated for the prediction of the long-term survival
rates of laryngeal cancer patients treated by these different methods. The lognormal model may
become a useful tool in research on outcomes.
Background
Literature review [1] indicated that local control, laryngeal
preservation, and survival rates of larynegeal cancer
patients were similar after transoral laser resection, open
partial laryngectomy, and radiotherapy. Open partial
laryngectomy was reserved for patients with locally recur-
rent tumors. There are still some unanswered questions.
Will radiation combined with surgery give a better result
than single modality treatment alone? Will treatment
results from the community centers follow published data
from prestigious centers? After radiotherapy, radio-resist-
ant cells theoretically may take some time to grow before
recurrence. Short-term data may not reflect long-term
local control and survival rates. We attempt to address
these questions in the present study.
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The lognormal distribution is defined as the distribution
of a random variable whose logarithm is normally distrib-
uted. The purpose of this study is to validate the use of the
lognormal model [2-4] by estimating the long-term sur-
vival from short-term follow-up data of laryngeal cancer
treated by three different treatment methods: radiation
and surgery, radiation alone, and surgery alone. We have
previously validated the application of the lognormal
model for small cell lung cancer [5], glottic laryngeal can-
cer [6], prostate cancer [7] and breast cancer [8].
This model may be useful for randomized clinical trials
because it allows the prediction of long-term survival rates
several years earlier than is possible by using the standard
actuarial life table/Kaplan-Meier method of calculation
[9].
The idea that long-term survival rates can be estimated
from short-term follow-up data is attractive because this
method shortens the delay in further research to improve
cancer treatment. The validation of the lognormal model
has two phases. Phase 1 tests the goodness of fit to a log-
normal distribution of the survival times of those cancer
patients who died with disease.
Phase 2 attempts to verify the lognormal model, which
uses short-term follow-up data to predict long-term sur-
vival rates. These survival rates are then compared with
values calculated by the Kaplan-Meier life table method
from available long-term data. The second phase has been
difficult to implement because of the general lack of large
number of patients with sufficiently long follow-up infor-
mation. With the SEER database [10], the validation of the
lognormal model is now possible.
Methods
We analyzed a total of 907 cases of laryngeal cancer
treated by three treatment methods: radiation and surgery
(248 patients), radiation alone (345 patients), and sur-
gery alone (314 patients), registered in two registries,
Connecticut and Metropolitan Detroit, from 1973–1977
with known survival status up to 1999 extracted from the
SEER database. Fourty-seven patients with unknown sur-
vival time and 165 patients with missing treatment meth-
ods were excluded. A table of the patient characteristics
was listed in Table 1.
The cause-specific survival time was defined as the interval
from the date of diagnosis to the date of death from laryn-
geal cancer or the date of last follow-up for censoring pur-
poses, if the patient was alive and still being followed at
the time of analysis. Patients who died of other causes
were also censored at date of death.
Phase 1 – Test of goodness of fit for lognormality
Testing for lognormality was done separately for laryngeal
cancer patients who died with disease (as distinct from
those who died of an intercurrent disease) treated by: radi-
ation and surgery, radiation alone, and surgery alone. For
Phase 1, a minimum chi-square method was used to esti-
mate the standard deviation S and mean M of the log10
(survival time) of the distribution of patients who died of
the cancer. The minimum chi-square test was run by a
Microsoft Excel program. A range of S-values and M-val-
ues were tested to reduce the chi-square values to a mini-
mum. In order to determine if the observed survival times
for a given cohort are lognormally distributed, the results
are given in terms of probability levels of significance P for
the chi-square estimates which correspond to a minimiza-
tion of chi-square and hence a maximization of P. The test
statistic of the minimum chi-square test was minimized
by varying the parameters and the P-value gave the signif-
icance of the test. The class intervals were in the powers of
2 in months of the survival time, such as 0–2, >2–4, >4–
8, >8–16, and so on. The number of cases in each interval
should not be less than 5. The null hypothesis being tested
is H0: that there is no difference between the observed sur-
vival times and the expected survival times calculated
from a lognormal distribution with a specified S and M. If
P < 0.05 the null hypothesis is rejected.
Phase 2 – Validation of the lognormal model
A second computer program for the Phase 2 of the study
was also run using Microsoft Excel to estimate the cured
fraction C by using a maximum likelihood method
described by Boag [4]. Using the lognormal model, the
Table 1: Patient Characteristics
Total number of 
patients
907
Median age 62 (range 21–96)
Patient Percent
Race:
White 828 91%
Black 75 8%
Others 4 1%
Sex:
Male 780 96%
Female 127 14%
Stage:
Localized 454 50%
Regional 286 31%
Distant 71 8%
Unstaged 50 6%
In Situ 46 5%BMC Cancer 2005, 5:13 http://www.biomedcentral.com/1471-2407/5/13
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standard deviation (S) was fixed, and only the two
remaining parameters, the mean (M) and the cured frac-
tion among all patients (C), were kept floating. Multiple
iterations converged to a stable solution for C. The cause-
specific survival rate (CSSR) at time τ = [C + (1-C) × Q] ×
100%, where Q = the integral of the lognormal distribu-
tion between the limits τ and infinity, τ = long-term sur-
vival time, C was calculated by the maximum likelihood
method.
The five-year cohort extended from 1973 to the end of
1977. Prediction of the long-term CSSR were made after
one year follow-up, i.e. at the end of 1978, for the laryn-
geal cancer patients with three different treatments: radia-
tion and surgery, radiation alone, and surgery alone. The
predicted CSSR were then validated by comparing with
the results calculated by the Kaplan-Meier method using
the actual follow-up data available up to 1999.
Log-rank tests were performed for the three different treat-
ment groups over the whole time period in order to see if
there was a difference in CSSR between treatments.
Results
Using data from 1973–1977, the minimum chi-square
tests verified that the survival times of the patients who
died of laryngeal cancer and who were treated by three
treatments followed three different lognormal distribu-
tions. At minimum chi-square, the S and M values, the
numbers of patients N and the P values of the minimum
chi-square tests for the three different treatments are listed
in Table 2.
Table 2: Phase 1 results for the three different treatments
Treatment method S M N P
Radiation and surgery 0.3623 1.3413 57 0.26
Radiation alone 0.5279 1.2740 86 0.66
Surgery alone 0.6938 1.5057 73 0.32
Abbreviations:
S = standard deviation of the lognormal distribution;
M = mean of the lognormal distribution;
N = number of patients;
P = P value for the minimum chi-square test.
Table 3: Cause-specific survival rates after one year of follow-up as predicted by the lognormal model compared with the actuarial 
results as calculated by the Kaplan-Meier method
(A) Radiation and Surgery:
Cause-specific survival rate (%)
Method Year 10 y 15 y 20 y 25 y C × 100%
L o g n o r m a l 1 9 7 8 7 47 37 27 27 2
KM 1999 74 ± 3 72 ± 3 72 ± 3 72 ± 3 --
(B) Radiation alone:
Cause-specific survival rate (%)
Method Year 10 y 15 y 20 y 25 y C × 100%
L o g n o r m a l 1 9 7 8 7 16 96 86 86 7
KM 1999 71 ± 3 68 ± 3 68 ± 3 68 ± 3 --
(C) Surgery alone:
Cause-specific survival rate (%)
Method Year 10 y 15 y 20 y 25 y C × 100%
L o g n o r m a l 1 9 7 8 7 47 06 76 56 1
KM 1999 77 ± 3 72 ± 3 68 ± 3 66 ± 4 --
y, year;
C × 100%, cured rate estimated by the lognormal model;
KM, Kaplan-Meier method ± one standard error.BMC Cancer 2005, 5:13 http://www.biomedcentral.com/1471-2407/5/13
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As in a prospective trial at interim analysis, Phase 2 was
performed for each of the five-year cohort periods after
one year of follow-up. Phase 2 predicted, using the maxi-
mum likelihood method, the long-term 10-, 15-, 20-, and
25-year CSSR. An S value was selected for the maximum
likelihood method, so that the prediction curve obtained
by the lognormal model would best fit the Kaplan-Meier
graph at one year after the five-year cohort period. Hence
at the time of prediction by the lognormal model, the
long-term data were not known yet. Table 3 lists the
results for each treatment arm and their comparison with
calculation obtained by the Kaplan-Meier method. The
predictions were validated by comparing them with the
Kaplan-Meier calculation using available data up to 1999.
The 25-year CSSR were predicted by the lognormal model
after only short term follow-up to be 72%, 68% and 65%
for treatments by radiation and surgery, radiation alone,
and surgery alone respectively. The 25-year CSSR were
found to be 72+/-3% (one standard error), 68+/-3% and
66+/-4% respectively by Kaplan-Meier method. Long-
term survival rates at other years, e.g. 10-, 15-, and 20-year
CSSR, were all within one standard error compared with
the Kaplan-Meier calculations.
There were no statistically significant differences between
the CSSR of the three different treatment groups for all
stages combined (p = 0.35 by log-rank test for the three
treatments).
Cause-specific survival for all patients with laryngeal cancer treated by radiation and surgery estimated by the lognormal model  at 1978 versus actuarial survival calculated by the Kaplan-Meier method at 1999 Figure 1
Cause-specific survival for all patients with laryngeal cancer treated by radiation and surgery estimated by the lognormal model 
at 1978 versus actuarial survival calculated by the Kaplan-Meier method at 1999.
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Figures 1, 2 and 3 show the comparisons of the three dif-
ferent treatments: radiation and surgery, radiation alone,
and surgery alone respectively for laryngeal cancer in the
Kaplan-Meier graph at the year 1999 compared with the
lognormal model prediction curve which could be
obtained at 1978.
The SEER database provides localized and regional disease
stages, instead of T1N0 or T2N0 stages, etc. The lognormal
model prediction of the 25-year CSSR for 454 patients
with localized stage disease were 84%, 75%, and 80% for
treatments by radiation and surgery, radiation alone, and
surgery alone respectively. The 25-year CSSR calculated by
the Kaplan-Meier method were 83+/-4%, 75+/-4%, and
77+/-6% respectively (p = 0.08, log-rank test for the three
treatments). For 286 patients with regional stage disease,
the 25-year CSSR were 62%, 58%, and 52% respectively,
and compared with Kaplan-Meier method were 63+/-6%,
58+/-7%, and 46+/-6% respectively (p = 0.76, log-rank
test for the three treatments).
Discussion
The current study demonstrates the application of the log-
normal model to a population based study. The lognor-
mal model is being applied in a manner that can be
applied to prospective trials in practice. Our previous pub-
lication about the application of the lognormal model
was for different stages of laryngeal cancer patients treated
Cause-specific survival for all patients with laryngeal cancer treated by radiation alone estimated by the lognormal model at  1978 versus actuarial survival calculated by the Kaplan-Meier method at 1999 Figure 2
Cause-specific survival for all patients with laryngeal cancer treated by radiation alone estimated by the lognormal model at 
1978 versus actuarial survival calculated by the Kaplan-Meier method at 1999.
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by one radiation oncologist, Dr. M. Lederman in the Royal
Marsden Hospital, United Kingdom [6]. The current study
shows that the lognormal model is applicable in different
scenarios.
Detroit and Connecticut registries were chosen because
they have the earliest data starting from 1973 and they
include a large population of both white and black
patients. Generally cause-specific death rates underesti-
mate the mortality associated with a diagnosis of the spe-
cific cancer, because some patients died of other
causes[11]. Gamel et al.[12] found that the follow-up time
should be one standard deviation beyond the mean of the
survival time so as to obtain stable results. In the current
study, five-year cohorts extended from 1973 to the end of
1977 were used. Stable results for prediction of the long-
term CSSR were obtained after one year of follow-up.
In this study, for localized stage disease 5-year CSSR were
91%, 83%, 95% for treatments by radiation and surgery,
radiation alone, and surgery alone respectively with Kap-
lan-Meier method.
Jones et al.[13] found that the 5-year tumor-specific sur-
vival for those treated by radiation was 87% and for those
treated by surgery was 77% (p = 0.1022). Both radiation
and surgery are equally effective for treating early stage
laryngeal carcinoma. In the current study, there were
marginal difference in the results of the three treatments
for localized stage patients.
Cause-specific survival for all patients with laryngeal cancer treated by surgery alone estimated by the lognormal model at 1978  versus actuarial survival calculated by the Kaplan-Meier method at 1999 Figure 3
Cause-specific survival for all patients with laryngeal cancer treated by surgery alone estimated by the lognormal model at 1978 
versus actuarial survival calculated by the Kaplan-Meier method at 1999.
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Jorgensen et al.[14] found that among patients with T1
glottic carcinomas the 5-year locoregional control rate was
88%, i.e. 88% of patients were cured by radiotherapy
alone. The 5-year disease-specific survival (DSS) was 99%,
i.e. salvage surgery added approximately 11% to the sur-
vival of T1 glottic patients. Only 4% (12/312) of T1 glottic
patients underwent laryngectomies. Locoregional control
among T2 glottic patients was 67% and the DSS 88%, and
18% (41/233) of patients underwent laryngectomies. The
corresponding results among T3 glottic patients were 30%
and 59%, about 50% of patients underwent
laryngectomies. For T3 glottic carcinomas, initial surgery
did not produce better survival rates.
Franchin et al.[15] studied T1 and T2 glottic carcinoma.
The 5-year and 10-year overall survival rates were 83%
and 63.5%, respectively. The overall 10-year local control
rate for patients with T1 and T2 glottic carcinoma was
89%.
In this study, the treatment results were marginally differ-
ent for localized stage (p = 0.08, log-rank test for the three
treatments) and the treatment results were similar for
regional stage (p = 0.76, log-rank test for the three treat-
ments). For localized stage combination radiation and
surgery may have more certainty of disease control and
hence long-term survival benefit. The treatment results
were similar for regional stage because the patients were
diagnosed late and disease control may be more difficult.
The predicted survivals were within one standard error of
the Kaplan-Meier estimations for both localized and
regional stages. It shows that the prediction method can
work for both good and poor prognosis cases.
The practical value of this study is that this lognormal
model may be used for prediction of the results of pro-
spective trials earlier than the Kaplan Meier method. This
lognormal model may become a useful tool in research
about outcomes. Use of this lognormal model could
result in more rapid advances in cancer treatment and
have the potential benefit of a reduction of cost in cancer
research.
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